Bextra Use Suspended By Kaiser; Celebrex Alzheimer’s Data Under Scrutiny

A decision by Kaiser Permanente physicians in California to stop prescribing Bextra demonstrates the challenges Pfizer must overcome as it seeks to reassure the public about the cardiovascular safety of COX-2 inhibitors